Analysis
Showing all blog posts in the Analysis category.
Next-Gen Obesity Drugs Compared: The 2026 Pipeline
Comparing retatrutide, orforglipron, amycretin, MariTide, survodutide, and VK2735 — mechanisms, efficacy data, and timelines as of April 2026.
Diet and Nutrition on Retatrutide: A Practical Guide
What to eat on retatrutide, how much protein you need, hydration strategies, and micronutrients to watch — based on clinical trial data.
Retatrutide Drug Interactions: What Clinicians Should Know
Analysis of potential retatrutide drug interactions based on GLP-1 class effects, including oral contraceptives, metformin, insulin, and anticoagulants.
Retatrutide and Hair Loss: What the Evidence Actually Says
Is retatrutide causing hair loss? A look at telogen effluvium during rapid weight loss, GLP-1 trial data, and what you can do about it.
Retatrutide and Sleep Apnea: What the TRIUMPH Data May Show
Clinical analysis of retatrutide's potential for obstructive sleep apnea based on TRIUMPH-2 protocols, tirzepatide precedent, and weight-loss-driven mechanisms.
Retatrutide and Weight Regain: What Happens When You Stop
Analysis of weight regain risk after stopping GLP-1 therapies and what retatrutide's TRIUMPH program tells us about long-term maintenance dosing.
Why You Can't Safely Buy Retatrutide Online: Gray Market Risks Explained
Retatrutide is widely available from online 'research peptide' vendors, but these products carry significant safety risks. This article explains why gray-market retatrutide is dangerous, what FDA enforcement actions have occurred, and why clinical-grade manufacturing matters.
What Will Retatrutide Cost? Analyzing Eli Lilly's Pricing Signals
No price announced for retatrutide, but tirzepatide pricing, the biologic lawsuit, analyst projections, and Lilly's $3.5B plant offer clues on future cost.
Retatrutide Dose Escalation Explained: Why Starting Low Matters
Understanding dose escalation in retatrutide and other GLP-1 class drugs — how gradual titration improves tolerability, what the Phase 2 trial revealed, and implications for clinical practice.
Retatrutide and Dysesthesia: What the Phase 3 Data Actually Shows
A clinical analysis of the dysesthesia signal observed in retatrutide's TRIUMPH-4 Phase 3 trial — incidence rates, severity, potential mechanisms, and what it means for regulatory review.
Retatrutide and Liver Fat: The MASLD Data That Changed the Conversation
An analysis of retatrutide's liver fat reduction data from Phase 2 imaging substudies, the role of glucagon receptor agonism in hepatic lipid metabolism, and the implications for MASLD/MASH as a therapeutic indication.
Does Retatrutide Preserve Muscle? What the Body Composition Data Shows
An evidence-based analysis of retatrutide's Phase 2 body composition substudy, examining the ratio of fat mass to lean mass loss and what it means for clinical outcomes.
How Phase 3 Changed Retatrutide's Dosing Protocol — and Why It Matters
An analysis of the key differences between retatrutide's Phase 2 and Phase 3 dose escalation protocols, the clinical rationale behind the changes, and what they signal about Eli Lilly's regulatory strategy.
Liver Fat Reduction With Retatrutide: Why the Phase 2 Data Are Significant
An in-depth analysis of retatrutide's approximately 82% liver fat reduction in Phase 2 — what it means for MASLD treatment, why glucagon receptor agonism drives the effect, and how it compares to other therapeutic approaches.
Putting 28.7% Weight Loss in Context: What Retatrutide's Numbers Mean
What does 28.7% mean body weight loss actually look like in clinical practice? Contextualizing retatrutide Phase 3 data against bariatric surgery, lifestyle intervention, and responder analysis.
Retatrutide vs. Mounjaro: Two Drugs, One Company, Different Targets
How Eli Lilly is developing both tirzepatide (Mounjaro/Zepbound) and retatrutide — examining dual vs. triple agonism, clinical differentiation, and portfolio strategy.
Retatrutide vs. Wegovy: What the Data Actually Shows
A cross-trial comparison of retatrutide and semaglutide 2.4 mg (Wegovy), examining weight loss efficacy, mechanism differences, and the limitations of indirect comparisons.
Retatrutide Side Effects: What Clinical Studies Actually Show
A factual, evidence-based summary of adverse events reported in retatrutide Phase 1 and Phase 2 clinical trials — gastrointestinal effects, dose-dependent patterns, discontinuation rates, and how they compare to other incretin-based therapies.
The TRIUMPH Phase 3 Program: Everything We Know
A comprehensive guide to Eli Lilly's TRIUMPH clinical trial program for retatrutide — individual trial designs, enrollment targets, primary endpoints, expected timelines, and what it all means for potential regulatory approval.
Why the Glucagon Receptor Matters: The Third Component of Triple Agonism
An analysis of why adding glucagon receptor agonism to GLP-1 and GIP activity makes retatrutide mechanistically distinct — and how glucagon's effects on energy expenditure, liver fat metabolism, and thermogenesis may drive superior clinical outcomes.
What Phase 3 Means: Understanding the TRIUMPH Program
An explanation of what Phase 3 clinical trials represent in drug development, what the TRIUMPH program is designed to answer, and what stakeholders should expect from retatrutide's pivotal trials.
Why Triple Agonism Matters: The Next Frontier in Metabolic Medicine
An analysis of why targeting three metabolic hormone receptors simultaneously represents a meaningful advancement over single and dual agonist approaches, and what it means for the future of obesity and diabetes treatment.
Breaking Down the Phase 2 Obesity Results: What the Numbers Actually Mean
A detailed analysis of retatrutide's Phase 2 obesity trial data published in the New England Journal of Medicine, explaining what the key endpoints and results signify for the field.
How to Read Clinical Trial Data: A Practical Guide for Non-Scientists
An educational guide explaining how to interpret clinical trial results, including endpoints, statistical significance, effect sizes, and common pitfalls, using examples from metabolic medicine research.